Okay, so What’s Next for Citius Pharma (CTXR) $1.16?

Dawson James Broker/Dealer Updates. Price Target Remains at $7.00. "OK, So what’s Next? Topline data from the superior efficacy...
Citius Pharma

Citius Pharma (CTXR) $1.20. Price Target Upped to $4.00 at HC Wainright.

STREET INSIDER H.C. Wainwright analyst Vernon Bernardino raised the price target on Citius Pharmaceuticals...
coronavirus, biotech stock review

VIDEO: Dyadic (DYAI) CEO Explains What his Industry is Doing to Defeat Coronavirus (FoxNews).

Jan. 27, 2020 - 5:24 - Dyadic International CEO Mark Emalfarb discusses what’s being done to stop...
Dyadic

Could Dyadic (DYAI) $5.75 Provide a Solution to Help Mass Produce Vaccines to Battle...

Dyadic (DYAI) has developed a biomanufacturing technology platform, nicknamed C1 which helps to speed the development, lower the manufacturing cost and potentially...
Immunomedics, Biotech Stock Review

Biotech 5 Pack. 5 Biotech Stocks We Expect to Double in 2020.

Our First Newsletter of 2020, We Come out Swinging! Yes, you read it right. Five of our favorite...
Citius Pharmaceutical, CTXR, Biotech Stock Review

New Report: Citius Pharma (CTXR) Now Our #1 Ranked Idea for 2020.

Citius Pharmaceuticals (CTXR) is hands down one of the most exciting long-term opportunities we have come across since we first launched the...

Citius Pharma (CTXR) Corporate Presentation (Jan 2020).

In the above graphic, the catheter can get infected by bacteria and most typically see evidence of the infection (see gross graphic...
Mitesco, Biotech Stock Review

Medtech Incubator True Nature | Mitesco (TNTY) Adds Another Heavy Hitter to Board.

True Nature Holding, Inc. DBA Mitesco, Inc. Adds Distinguished Healthcare Executive to Board of Directors.
Julie R Smith, True Nature, Mitesco

True Nature|Mitesco President & COO, Julie Smith Interview.

Julie R. Smith is a seasoned senior executive...

True Nature|Mitesco (TNTY). Coverage Report Issued.

Record Volume and Gradually Rising Price Portends to Higher Prices in 2020 as True Nature Executes on Recently Announced Incubator Strategy.

Latest article

GeoVax (GOVX) Provides First Half 2024 Business Update.

Award of BARDA Project NextGen contract represents a significant milestone event; Total value...

Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.

Can You Imagine Selling Solgenix at $2.00 yesterday. And to be honest, news wasn't all that big - such...

Nine Page Summary Report on GeoVax (GOVX)

This is a great long-term story. We’re telling you. When we finished writing our earlier 44-page report,...